PL424453A1 - Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) - Google Patents
Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)Info
- Publication number
- PL424453A1 PL424453A1 PL424453A PL42445318A PL424453A1 PL 424453 A1 PL424453 A1 PL 424453A1 PL 424453 A PL424453 A PL 424453A PL 42445318 A PL42445318 A PL 42445318A PL 424453 A1 PL424453 A1 PL 424453A1
- Authority
- PL
- Poland
- Prior art keywords
- endopeptidase
- hsep
- nep
- perenchymatous
- inhibitors
- Prior art date
Links
- 102000003729 Neprilysin Human genes 0.000 title abstract 4
- 108090000028 Neprilysin Proteins 0.000 title abstract 4
- 102000005593 Endopeptidases Human genes 0.000 title abstract 2
- 108010059378 Endopeptidases Proteins 0.000 title abstract 2
- 230000007812 deficiency Effects 0.000 title abstract 2
- 230000010412 perfusion Effects 0.000 title abstract 2
- 230000009931 harmful effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 210000000056 organ Anatomy 0.000 title 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 abstract 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical class N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 abstract 1
- QJJDBWAEIBNZPQ-UHFFFAOYSA-N 2-(3h-1,2-benzothiazepin-2-yl)acetic acid Chemical class S1N(CC(=O)O)CC=CC2=CC=CC=C21 QJJDBWAEIBNZPQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004738 parenchymal cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 phosphono-substituted benzazepinone Chemical class 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Zgłoszenie dotyczy nowego zastosowania pochodnych benzazepiny, benzoksazepiny, kwasu benzotiazepino-N-octowego oraz fosfono-podstawionego benzazepinonu o aktywności hamującej obojętną endopeptydazę (NEP) i/lub ludzką rozpuszczalną endopeptydazę (hSEP). Związki te są stosowane do wytwarzania kompozycji farmaceutycznych zmniejszających szkodliwy wpływ bezobjawowo postępującego rozsianego niedoboru perfuzji narządów miąższowych, lub ich części, mogącego sugerować rozwój chorób układowych.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL424453A PL424453A1 (pl) | 2018-01-31 | 2018-01-31 | Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) |
CA3088969A CA3088969A1 (en) | 2018-01-31 | 2019-01-31 | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs |
RU2020125051A RU2782919C2 (ru) | 2018-01-31 | 2019-01-31 | ИНГИБИТОРЫ НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ (НЭП) И РАСТВОРИМОЙ ЭНДОПЕПТИДАЗЫ ЧЕЛОВЕКА (РЭПч) ДЛЯ УМЕНЬШЕНИЯ ВРЕДНЫХ ВОЗДЕЙСТВИЙ ПЕРФУЗИОННОГО ДЕФИЦИТА ОРГАНОВ |
KR1020207025024A KR20200116144A (ko) | 2018-01-31 | 2019-01-31 | 기관의 관류 결핍의 해로운 효과를 감소시키기 위한 중성 엔도펩티다제 (NEP) 및 사람 용해성 엔도펩티다제 (hSEP) 억제제 |
EP19747045.3A EP3746107A4 (en) | 2018-01-31 | 2019-01-31 | NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (HSEP) INHIBITORS TO REDUCE THE HARMFUL EFFECTS OF ORGAN PERFUSION DEFICIENCY |
MX2020007990A MX2020007990A (es) | 2018-01-31 | 2019-01-31 | Inhibidores de endopeptidasa neutra (nep) y endopeptidasa soluble humana (hsep) para reducir efectos perjudiciales de la deficiencia de perfusion de organos. |
CN201980011178.7A CN111989112A (zh) | 2018-01-31 | 2019-01-31 | 用于减少器官灌流不足的有害效应的中性内肽酶(nep)及人类可溶性内肽酶(hsep)抑制剂 |
US16/964,984 US20210047352A1 (en) | 2018-01-31 | 2019-01-31 | NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS TO REDUCE DETRIMENTAL EFFECTS OF PERFUSION DEFICIENCY OF PARENCHYMAL ORGANS |
PCT/PL2019/000013 WO2019151883A1 (en) | 2018-01-31 | 2019-01-31 | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs |
ZA2019/05958A ZA201905958B (en) | 2018-01-31 | 2019-09-10 | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs |
IL275994A IL275994A (en) | 2018-01-31 | 2020-07-12 | Human neutral endopeptidase and soluble endopeptidase inhibitors to reduce harmful effects of organ hypoperfusion |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL424453A PL424453A1 (pl) | 2018-01-31 | 2018-01-31 | Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) |
Publications (1)
Publication Number | Publication Date |
---|---|
PL424453A1 true PL424453A1 (pl) | 2019-08-12 |
Family
ID=67478773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL424453A PL424453A1 (pl) | 2018-01-31 | 2018-01-31 | Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210047352A1 (pl) |
EP (1) | EP3746107A4 (pl) |
KR (1) | KR20200116144A (pl) |
CN (1) | CN111989112A (pl) |
CA (1) | CA3088969A1 (pl) |
IL (1) | IL275994A (pl) |
MX (1) | MX2020007990A (pl) |
PL (1) | PL424453A1 (pl) |
WO (1) | WO2019151883A1 (pl) |
ZA (1) | ZA201905958B (pl) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL184336B1 (pl) * | 1995-03-23 | 2002-10-31 | Solvay Pharm Gmbh | Pochodne kwasu benzazepino-, benzoksazepino-i benzotiazepino-N-octowego, sposób ich wytwarzania oraz zawierające je środki lecznicze |
EP1706121A1 (en) * | 2004-01-12 | 2006-10-04 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
DE19750002A1 (de) * | 1997-11-12 | 1999-05-20 | Solvay Pharm Gmbh | Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
AR046454A1 (es) * | 2003-11-18 | 2005-12-07 | Solvay Pharm Gmbh | Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica |
WO2005112940A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors |
-
2018
- 2018-01-31 PL PL424453A patent/PL424453A1/pl unknown
-
2019
- 2019-01-31 KR KR1020207025024A patent/KR20200116144A/ko not_active Application Discontinuation
- 2019-01-31 CN CN201980011178.7A patent/CN111989112A/zh active Pending
- 2019-01-31 WO PCT/PL2019/000013 patent/WO2019151883A1/en unknown
- 2019-01-31 EP EP19747045.3A patent/EP3746107A4/en active Pending
- 2019-01-31 CA CA3088969A patent/CA3088969A1/en active Pending
- 2019-01-31 US US16/964,984 patent/US20210047352A1/en active Pending
- 2019-01-31 MX MX2020007990A patent/MX2020007990A/es unknown
- 2019-09-10 ZA ZA2019/05958A patent/ZA201905958B/en unknown
-
2020
- 2020-07-12 IL IL275994A patent/IL275994A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL184336B1 (pl) * | 1995-03-23 | 2002-10-31 | Solvay Pharm Gmbh | Pochodne kwasu benzazepino-, benzoksazepino-i benzotiazepino-N-octowego, sposób ich wytwarzania oraz zawierające je środki lecznicze |
EP1706121A1 (en) * | 2004-01-12 | 2006-10-04 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders |
Non-Patent Citations (1)
Title |
---|
BOGNA BROCKHUIS, ZABURZENIA PERFUZJI MÓZGOWEJ OCENIONE METODĄ TOMOGRAFII EMISYJNEJ POJEDYNCZEGO FOTONU (SPECT) U PACJENTÓW Z OTĘPIENIEM Z CIAŁAMI LEWY'EGO, CHOROBĄ PARKINSONA ORAZ CHOROBĄ ALZHEIMERA, 2009 * |
Also Published As
Publication number | Publication date |
---|---|
US20210047352A1 (en) | 2021-02-18 |
CN111989112A (zh) | 2020-11-24 |
IL275994A (en) | 2020-08-31 |
ZA201905958B (en) | 2021-07-28 |
RU2020125051A (ru) | 2022-02-28 |
EP3746107A4 (en) | 2022-01-12 |
WO2019151883A1 (en) | 2019-08-08 |
RU2020125051A3 (pl) | 2022-02-28 |
KR20200116144A (ko) | 2020-10-08 |
CA3088969A1 (en) | 2019-08-08 |
EP3746107A1 (en) | 2020-12-09 |
MX2020007990A (es) | 2020-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022003782A2 (es) | Inhibidores de kras g12d | |
CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
DOP2022000115A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
SV2010003559A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
DOP2013000104A (es) | Antagonistas de mdm2 de espiro-oxindol | |
DOP2013000105A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
GT200900192A (es) | Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).- | |
EA201591499A1 (ru) | Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза) | |
EA201690888A1 (ru) | Новые гетероциклические соединения | |
EA201992679A1 (ru) | N-замещенные индольные производные | |
ECSP066931A (es) | Nuevos imidazoles | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
AR063027A1 (es) | Derivados de sulfonamida | |
MX2020008929A (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico. | |
EA202090995A1 (ru) | Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1 | |
EA201690077A1 (ru) | Терапевтически активные производные эстратриен-тиазола |